Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GDC-0973 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GDC-0973 Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GDC-0973 | DRUG | Single oral dose of \[14C\]-GDC-0973 |
Inclusion Criteria: * Body mass index (BMI) between 18.5 and 29.9 kg/m2, inclusive * No clinically significant findings from medical history, 12-lead ECG, and vital signs and laboratory evaluations * Negative test for selected drugs of abuse * No infection with hepatitis B, hepatitis C, human immun...
GDC-0973 is an investigational small molecule being developed by Roche Holding AG (ticker: RHHBY). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, with one completed clinical trial involving 6 participants.
GDC-0973 is being studied for use in healthy volunteers. The completed Phase 1 trial was a pharmacokinetics study in healthy male volunteers. The drug is still in clinical development and is not approved for any indication.
GDC-0973 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company conducted a Phase 1 clinical trial of the drug in the United States.
GDC-0973 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
GDC-0973 has one completed clinical trial, NCT01711762, titled "A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers." This Phase 1 study enrolled 6 healthy male participants in the United States.